• NeoGenomics, Inc. previously announced that Alicia Olivo, EVP, General Counsel & Business Development, would step down as General Counsel in September 2026 and remain with the company until early October 2026 to support the transition.
• The company also secured a favorable North Carolina court ruling that invalidated key Natera patents, reducing legal friction around its RaDaR ST assay and altering the competitive landscape in molecular residual disease testing.
• We’ll now examine how this legal victory over Natera shapes NeoGenomics’ investment narrative, particularly around RaDaR ST’s competitive positioning.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe that its expanding oncology test menu, especially in NGS and MRD, can eventually support more consistent earnings despite current losses. The North Carolina ruling that invalidated key Natera patents directly reduces legal uncertainty around RaDaR ST, improving visibility for one of NeoGenomics’ most important near term growth drivers, while competition and execution around new product launches remain the biggest near term risks.

Among recent announcements, the commercial launch and growing footprint of the PanTracer liquid biopsy and PanTracer Pro portfolio is most relevant here, because it highlights NeoGenomics’ push to pair MRD (including RaDaR ST) with broader CGP offerings. Together, PanTracer and RaDaR ST form a more complete oncology testing suite, which could help NeoGenomics deepen relationships with oncologists and health systems if adoption and reimbursement continue to progress as planned.

However, against this improving legal backdrop, investors should still be aware that...

NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029. This requires 9.2% yearly revenue growth and a $116 million earnings increase from -$51.9 million today.

Uncover how NeoGenomics' forecasts yield a $19.72 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts are far more cautious than the consensus, assuming about US$995,000,000 in 2029 revenue and continued losses, so you should treat this legal win as one new data point that could shift either the more optimistic or more pessimistic product execution narratives over time.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth as much as 89% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your NeoGenomics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.